I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter @theroberthart or email me at [email protected]
their hotly-anticipated Covid-19 vaccine will be delayed until 2022 to complete a clinical trial, unusually announcing the shot works as a booster before being able to demonstrate its effectiveness for primary immunization. dpa/picture alliance via Getty ImagesA single booster dose of the Sanofi and GSK Covid-19 vaccine provokes a “strong immune response” and has “a good safety and tolerability profile,” according to preliminary data from a clinical trial, the companies said.
The companies said they plan to file booster data with regulators following results from main clinical trials, expected in the first quarter of 2022. Regulators often require data on how well the shot can protect against infection when used on its own before approving it as a booster, the companies explained.
An advisory board recommended the companies delay the late-stage trial until more participants contract Covid to get more data on the shot’s efficacy. Sanofi and GSK are two of the biggest hitters in the pharmaceutical world and could still play a significant role in tackling the pandemic. Their failure to bring a vaccine to market during the first wave of shots was, in Sanofi’s case, a source ofto France and a major dent to the global vaccine drive.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Covid: Booster push to tackle Omicron and new working from home guidanceFive things you need to know about the coronavirus pandemic this Monday morning.
Consulte Mais informação »
Covid booster jabs: Why people say they are worth queueing forPeople explain why they're happy to wait in line for their third Covid vaccination.
Consulte Mais informação »
Vaccines appear weak at blocking Omicron infection; shots may reduce long COVID burdenThe following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
Consulte Mais informação »
Dear Care and Feeding: How Do I Help My Teen Who’s Been Ghosted by Her Friends?My daughter’s friends told her she was too weird and uncool and that’s why they dropped her.
Consulte Mais informação »
Only half of US nursing home residents have received a Covid-19 vaccine boosterOnly about half of fully vaccinated nursing home residents have received a booster dose of Covid-19 vaccine, leaving a high-risk group especially vulnerable as Covid-19 cases rise across the country and concern about the Omicron variant builds.
Consulte Mais informação »
So, are we going to need COVID-19 boosters forever?Experts discuss the potential need for more boosters and what the future of COVID-19 boosters might look like.
Consulte Mais informação »